Designing development programs for non-traditional antibacterial agents

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Rex, John H ^a,b   Fernandez Lynch, Holly ^c   Cohen, I Glenn ^d,e   Darrow, Jonathan J ^f   Outterson, Kevin ^g  

^a F2G LTD   (United Kingdom)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HARVARD LAW SCHOOL   (United States)

^e Petrie Flom Center for Health Law Policy   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; POLYMYXIN B; PROBIOTIC AGENT; RAXIBACUMAB; VIRULENCE FACTOR;

ANTIMICROBIAL ACTIVITY; BACTERIUM; DESIGN METHOD; DRUG; STANDARD (REFERENCE);

ANTIBIOFILM ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL STEWARDSHIP; BACTERIAL VIRULENCE; BACTERIOPHAGE; CLINICAL OUTCOME; DISEASE TRANSMISSION; DRUG DESIGN; HIGH INCOME COUNTRY; HUMAN; IMMUNE RESPONSE; MICROBIOME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROGRAM DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRADITIONAL MEDICINE; VACCINATION; BACTERIUM; DRUG EFFECT; SYNTHESIS;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DESIGN; HUMANS;

EID: 85070916631     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-11303-9     Document Type: Review

References (66)

1. Review on Antimicrobial Resistance. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Available online at http://amr-review.org/ (2016 May). This final paper from a multi-year effort to review the economic challenges surrounding antimicrobial resistance provides a thorough review of the entire area.
2. World Bank Group. Drug-Resistant Infections: A Threat to Our Economic Future. http://documents.worldbank.org/curated/en/323311493396993758/pdf/final-report.pdf (2017). Accessed 26 June 2019.
3. Tse, B. N. et al. Challenges and opportunities of nontraditional approaches to treating bacterial infections. Clin. Infect. Dis. 65, 495–500 (2017). This paper offers a survey of the reasons why alternatives to antibiotics have intrigued many developers.
4. Opal, S. M. Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance. Crit. Care 20, 397 (2016).
5. Czaplewski, L. et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect. Dis. 16, 239–251 (2016). Commissioned by Wellcome Trust, this paper is the output of a collaborative review of alternatives undertaken by a group of 24 academic and industry scientists.
6. Theuretzbacher, U. & Piddock, L. J. V. Non-traditional Antibacterial Therapeutic Options and Challenges. Cell Host Microbe. 26, 61–72 (2019).
7. Outterson K. New business models for sustainable antibiotics. Chatham House. http://www.chathamhouse.org/publications/papers/view/197446 (2014). Downloaded 2 Mar 2014.
8. Sertkaya, A. et al. Analytical framework for examining the value of antibacterial products. Report to US DHHS. United States Department of Health and Human Services. http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm (2014). Downloaded 17 June 2014.
9. Ardal, C. et al. Developing new economic models to incentivise antibiotic discovery and development activities while safeguarding the efficacy of antibiotics by researching and advocating their appropriate use. http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf (2018). Accessed 14 Oct 2018.
10. Ardal, C., Rottingen, J. A., Opalska, A., Van Hengel, A. J. & Larsen, J. Pull incentives for antibacterial drug development: an analysis by the transatlantic task force on antimicrobial resistance. Clin. Infect. Dis. 65, 1378–1382 (2017).
11. Kasumov A. Novartis Exits Antibiotics Research, Cuts 140 Jobs in Bay Area. Bloomberg News. https://www.bloomberg.com/news/articles/2018-07-11/novartis-exits-antibiotics-research-cuts-140-jobs-in-bay-area (2018). Downloaded 26 Nov 2018.
12. Paton, J. & Kresge, N. Superbugs Win Another Round as Big Pharma Leaves Antibiotics. Bloomberg News. https://www.bloomberg.com/news/articles/2018-07-13/superbugs-win-another-round-as-big-pharma-leaves-antibiotics (2018). Downloaded 26 Nov 2018.
13. Theuretzbacher, U., Savic, M., Ardal, C. & Outterson, K. Market watch: innovation in the preclinical antibiotic pipeline. Nat. Rev. Drug. Discov. 16, 744–745 (2017).
14. de Gunzburg, J. et al. Protection of the human gut microbiome from antibiotics. J. Infect. Dis. 217, 628–636 (2018).
15. Laterre, P. F. et al. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 19, 620–630 (2019).
16. Marineli, F., Tsoucalas, G., Karamanou, M. & Androutsos, G. Mary Mallon (1869–1938) and the history of typhoid fever. Ann. Gastroenterol. 26, 132–134 (2013).
17. Corbett, D. et al. Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741. Antimicrob. Agents Chemother. 61, e00200-e00217 (2017).
18. Sparrow, E., Friede, M., Sheikh, M. & Torvaldsen, S. Therapeutic antibodies for infectious diseases. Bull. World Health Organ. 95, 235–237 (2017).
19. Wagner, E. K. & Maynard, J. A. Engineering therapeutic antibodies to combat infectious diseases. Curr. Opin. Chem. Eng. 19, 131–141 (2018).
20. Head, B. M., Rubinstein, E. & Meyers, A. F. Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect. Dis. 16, 621 (2016).
21. Huygen, K. Development of human monoclonal antibodies to diphtheria toxin: a solution for the increasing lack of equine DAT for therapeutic use? Virulence 7, 613–615 (2016).
22. Anonymous. Investigational Heptavalent Botulinum Antitoxin (HBAT) to Replace Licensed Botulinum Antitoxin AB and Investigational Botulinum Antitoxin E. MMWR Morb. Mortal. Wkly. Rep. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5910a4.htm (2010). Accessed 26 June 2019.
23. Blake, P. A., Feldman, R. A., Buchanan, T. M., Brooks, G. F. & Bennett, J. V. Serologic therapy of tetanus in the United States, 1965–1971. J. Am. Med. Assoc. 235, 42–44 (1976).
24. Gerding, D. N. et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection in patients at increased risk for recurrence. Clin. Infect. Dis. 67, 649–656 (2018).
25. Wright, G. D. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol. 24, 862–871 (2016). This paper summarizes the scientifc principles behind creation of combination products, a strategy that is fundamental to many alternative products.
26. McDonnell, A. M. et al. Efficient delivery of investigational antibacterial agents via sustainable clinical trial networks. Clin. Infect. Dis. 63(Suppl. 2), S57–S59 (2016).
27. Rex, J. H. et al. Progress in the fight against multidrug-resistant bacteria 2005-2016: modern non-inferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin. Infect. Dis. 65, 141–146 (2017). Over the past 10 years there have been many improvements in the approach to non-inferiority trial designs; this paper summarizes the relevant background and key principles.
28. Rex, J. H. et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect. Dis. 13, 269–275 (2013).
29. Code of Federal Regulations. 21 C.F.R. § 300.50 (“Fixed-combination prescription drugs for humans”), https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=300.50 (2011).
30. Food and Drug Administration, Center for Drug Evaluation. Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway—Guidance for Industry. US Dept HHS, FDA, CDER, CBER. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (2019). Accessed 10 Feb 2019.
31. FDA-NIH Biomarker Working Group: BEST (Biomarkers E, and other Tools) Resource. Reasonably Likely Surrogate Endpoint. Food and Drug Administration (US) / Co-published by National Institutes of Health (US), Bethesda (MD). https://www.ncbi.nlm.nih.gov/books/NBK453485/ (2017). Accessed 6 June 2019.
32. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
33. Darrow, J. J., Sinha, M. S. & Kesselheim, A. S. When markets fail: patents and infectious disease products. Food Drug Law J. 73, 361–382 (2018).
34. Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA 111, 787–792 (2014).
35. Jochems, S. P., Weiser, J. N., Malley, R. & Ferreira, D. M. The immunological mechanisms that control pneumococcal carriage. PLoS. Pathog. 13, e1006665 (2017).
36. Tacconelli, E. et al. ESCMID-EUCIC clinical guidelines on decolonisation of multidrug-resistant Gram-negative bacteria carriers. Clin. Microbiol. Infect. 25, 807–817 (2019).
37. Fleming, T. R. & Powers, J. H. Biomarkers and surrogate endpoints in clinical trials. Stat. Med. 31, 2973–2984 (2012).
38. Committee for Medicinal Products for Human Use (CHMP). Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. European Medicines Agency, EMA/CHMP/351889/2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf (2013). Downloaded 1 May 2015.
39. Miller, F. G. & Joffe, S. Equipoise and the dilemma of randomized clinical trials. N. Engl. J. Med. 364, 476–480 (2011). This paper argues that equipoise is not a requirement for ethical research.
40. Garattini, S. & Bertele, V. Non-inferiority trials are unethical because they disregard patients’ interests. Lancet 370, 1875–1877 (2007).
41. Graber, M. A., Ely, J. & Faine, B. A. Are noninferiority studies ethically inferior? Am. J. Health Syst. Pharm. 75, 911–914 (2018).
42. Hey, S. P. & Kesselheim, A. S. Reprioritizing research activity for the post-antibiotic era: ethical, legal, and social considerations. Hastings Cent. Rep. 47, 16–20 (2017).
43. Megiddo. I. et al. Investing in antibiotics to alleviate future catastrophic outcomes: what is the value of having an effective antibiotic to mitigate pandemic influenza? Health Econ. 10.1002/hec.3867 (2019).
44. Emanuel, E. J., Wendler, D., Killen, J. & Grady, C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. J. Infect. Dis. 189, 930–937 (2004).
45. Code of Federal Regulations. 45 C.F.R. § 46.111(a)(2) (“Criteria for IRB approval of research”), https://www.ecfr.gov/cgi-bin/text-idx?SID=855b4516c632063a1db33520391a59e8&mc=true&tpl=/ecfrbrowse/Title45/45cfr46_main_02.tpl (2018).
46. Code of Federal Regulations. 21 C.F.R. § 56.111(a)(2) (“Criteria for IRB approval of research”), https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=56.111 (2018).
47. Rid, A. & Shah, S. K. Substantiating the social value requirement for research: an introduction. Bioethics 31, 72–76 (2017).
48. Miller, F. G. & Joffe, S. Limits to research risks. J. Med. Ethics 35, 445–449 (2009).
49. Weijer, C. & Miller, P. B. When are research risks reasonable in relation to anticipated benefits? Nat. Med. 10, 570–573 (2004). This paper explores a practical approach to evaluating a study’s risks and benefits to determine whether it is ethically acceptable to carry out.
50. Doshi, P. et al. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. JAMA Intern. Med. 177, 1–8 (2017).
51. Menikoff, J. What should patients be told about noninferiority studies? JAMA Intern. Med. 177, 1459–1460 (2017).
52. Joffe, S. & Miller, F. G. Equipoise: asking the right questions for clinical trial design. Nat. Rev. Clin. Oncol. 9, 230–235 (2012).
53. Gelinas, L., Lynch, H. F., Bierer, B. E. & Cohen, I. G. When clinical trials compete: prioritising study recruitment. J. Med. Ethics 43, 803–809 (2017).
54. Anomaly, J. & Savulescu, J. Compensation for cures: why we should pay a premium for participation in ‘challenge studies’. Bioethics. 10.1111/bioe.12596 (2019).
55. Temple, R. & Ellenberg, S. S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann. Intern. Med. 133, 455–463 (2000).
56. Ellenberg, S. S. & Temple, R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann. Intern. Med. 133, 464–470 (2000).
57. Powers, J. H. & Fleming, T. R. Noninferiority trials: clinical understandings and misunderstandings. Clin. Investig. 3, 215–218 (2013).
58. Kaul, S. & Diamond, G. A. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann. Intern. Med. 145, 62–69 (2006).
59. Powers, J. H., Evans, S. R. & Kesselheim, A. S. Studying new antibiotics for multidrug resistant infections: are today’s patients paying for unproved future benefits? Br. Med. J. 360, k587 (2018). This paper summarizes the pitfalls of non-inferiority trials.
60. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1–12 (1998).
61. Craig, W. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1), S6–S8 (1993).
62. Ambrose, P. G. et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It’s not just for mice anymore. Clin. Infect. Dis. 44, 79–86 (2007).
63. Ambrose, P. G., Bhavnani, S. M., Ellis-Grosse, E. J. & Drusano, G. L. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin. Infect. Dis. 51, S103–S110 (2010).
64. Ambrose, P. G. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design. Clin. Infect. Dis. 47, S225–S231 (2008).
65. Peck, C. C., Rubin, D. B. & Sheiner, L. B. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin. Pharmacol. Ther. 73, 481–490 (2003).
66. Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17, 141–145 (2019).